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aBStract
CONTEXT AND OBJECTIVE: Breast cancer accounts for approximately one quarter of all cancers in fe-
males. Estrogen and progesterone receptor testing has become an essential part of the clinical evaluation 
of breast carcinoma patients, and accurate results are critical in identifying patients who may benefit from 
hormone therapy. The present study had the aim of investigating the concordance of the results from 
hormone receptor tests between a reference laboratory and local (or community) laboratories in Brazil. 
DESIGN AND SETTING: Retrospective study at a reference pathology laboratory.
METHODS: The concordance in the results from hormone receptor tests between a reference laboratory 
and 146 local laboratories in Brazil was compared in relation to 500 invasive breast carcinoma cases, using 
immunohistochemistry. 
RESULTS: There was concordance in 89.4% (447/500 cases) and 85.0% (425/500 cases) of the results from 
estrogen (k = 0.744, P < 0.001) and progesterone (k = 0.688, P < 0.001) receptor tests, respectively, be-
tween local and reference laboratories. This was similar to findings in other countries. The false negative 
rates from estrogen and progesterone receptor tests in local laboratories were 8.7% and 14.4%, respec-
tively. The false positive rates from estrogen and progesterone receptor tests in local laboratories were 
15.5% and 16.0%, respectively.
CONCLUSION: Technical and result interpretation issues may explain most of the discordances in hor-
mone receptor testing in local laboratories. Validation of estrogen and progesterone receptor tests at local 
laboratories, with rigorous quality control measures, is strongly recommended in order to avoid erroneous 
treatment of breast cancer patients. 
reSUMO
CONTEXTO E OBJETIVO: O carcinoma de mama é responsável por cerca de um quarto de todos os cân-
ceres em mulheres. O teste de receptores de estrógeno e progesterona se tornou parte essencial da ava-
liação clínica de pacientes com carcinoma de mama; assim, resultados precisos são fundamentais para 
identificação de pacientes que podem se beneficiar da terapia hormonal. O presente estudo tem por 
objetivo investigar a concordância nos resultados do teste de receptores hormonais entre um laboratório 
referência e laboratórios locais (ou comunitários) do Brasil.
TIPO DE ESTUDO E LOCAL: Estudo retrospectivo em laboratório referência em patologia no Brasil.
MÉTODOS: A concordância nos resultados dos testes de receptores hormonais entre um laboratório re-
ferência e 146 diferentes laboratórios locais brasileiros foi comparada em 500 casos de carcinoma invasivo 
de mama através da imunoistoquímica.
RESULTADOS: Houve concordância de 89,4% (447/500 casos) e 85,0% (425/500 casos) nos resultados dos 
testes de receptores de estrógeno (k = 0,744, P < 0,001) e progesterona (k = 0,688, P < 0,001), respecti-
vamente, entre laboratórios locais e referência, similar à descrita em outros países. A taxa de resultados 
falso-negativos nos testes de receptores de estrógeno e progesterona em laboratórios locais foi de 8,7% 
e 14,4%, respectivamente. A taxa de resultados falso-positivos nos testes de receptores de estrógeno e 
progesterona em laboratórios locais foi de 15,5% e 16,0%, respectivamente. 
CONCLUSÃO: Questões técnicas e de interpretação dos resultados podem explicar a maior parte das 
discordâncias nos testes de receptores hormonais em laboratórios locais. A validação dos testes de re-
ceptores de estrógeno e progesterona pelos laboratórios locais com medidas de controle de qualidade 
rigorosas é fortemente recomendada de modo a evitar o tratamento errôneo de pacientes com carcino-
ma de mama.
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INTRODUCTION
Breast cancer is one of the most common human neoplasms, 
accounting for one quarter of all cancers in females.1 Hormone 
therapy is frequently used in breast carcinoma treatment because 
it reduces the relative risk of recurrence by more than 50% in 
patients with hormone-sensitive tumors, thus leading to signifi-
cant improvements in survival. For these reasons, determination 
of estrogen receptor (ER) and progesterone receptor (PgR) status 
has become an essential part of the clinical evaluation of all breast 
carcinoma patients, and accurate results are critical in identify-
ing patients who may benefit from hormone therapy.2-8 Immu-
nohistochemistry (IHC) is currently the most common method 
used for determining ER and PgR status. Low cost and applica-
bility to routinely processed and archived tissue samples are the 
main advantages of IHC. However, discordances in ER and PgR 
testing have been reported in the literature, and they have been 
mostly correlated with technical issues, including fixative and fix-
ation issues, immunohistochemical methodology and diversity 
of interpretation of results.9-29
OBJECTIVE
Considering that the accuracy of ER and PgR testing in breast 
carcinoma is extremely important in selecting the hormone ther-
apy, the present study had the aim of investigating the concor-
dance of the results from ER and PgR tests using IHC between 
a reference laboratory (Pathology Consultancy, Botucatu, São 
Paulo, Brazil) and local (or community) laboratories in Brazil.
METHODS
Institutional certifications
This study was approved by the Scientific Committee of the 
Department of Pathology, Faculdade de Medicina da Univer-
sidade de São Paulo (FMUSP), and by the Ethics Committee 
for Research Projects of Hospital das Clínicas (HC), FMUSP 
(CAPPesq, protocol no 1238/09).
Validation at the reference laboratory 
For any clinical assay to be validated, the results need to be com-
pared with a standard. For ER and PgR testing, the recommended 
approach towards validation is based on comparison of the assay 
results with results obtained by another laboratory using a test-
ing method that has been previously validated against the clini-
cal outcome or using proficiency-testing material that has been 
validated by showing a consensus of results among multiple lab-
oratories in a peer group (which must include laboratories with 
validated assays). ER and PgR IHC assays that are not subjected 
to direct clinical validation may be validated by showing at least 
90% agreement for positive results and at least 95% agreement for 
negative results (a minimum of 20 positive and 20 negative speci-
mens are required) with testing performed on the same material 
in another laboratory that provides written attestation that it is in 
conformity with the testing requirements of the American Society 
of Clinical Oncology (ASCO) and College of American Patholo-
gists (CAP) and that offers fully validated ER and PgR assays.6,7,30 
Pathology Consultancy, a reference laboratory located in 
Botucatu, São Paulo State, Brazil, performs approximately 7,000 
ER and PgR assays by means of IHC annually. In order to fur-
ther validate the ER and PgR testing by Pathology Consultancy, 
we compared the results from ER and PgR IHC assays between 
a CAP-accredited laboratory that performs fully validated ER 
and PgR testing (PhenoPath Laboratories, Seattle, Washington, 
United States) and Pathology Consultancy. For validation pur-
poses, 255 invasive breast carcinoma samples (a 2-mm tissue core 
for each sample) were distributed over nine tissue microarray 
(TMA) blocks. Unstained 3-μm-thick histological sections from 
each TMA block were obtained and used to determine the ER 
and PgR status using IHC, both in PhenoPath Laboratories and 
in Pathology Consultancy. 
In Pathology Consultancy, the sections were deparaffinized 
in xylene and rehydrated in graded alcohols and phosphate-buff-
ered saline (PBS). The sections were then subjected to antigen 
retrieval in a pressure pan using citric acid (0.21%, pH 6.0) for a 
total of eight minutes, followed by a 20-minute cool-down period 
at room temperature. Subsequently, the slides were incubated 
overnight with the primary antibody. The SP1 rabbit monoclo-
nal antibody (code RM-9101-S, Thermo Fisher Scientific, Fre-
mont, California, United States; dilution 1:1000) was used for ER 
testing. The PgR 636 mouse monoclonal antibody (code M3569, 
Dako, Carpinteria, California, United States; dilution 1:1600) 
was used for PgR testing. After incubation with the primary anti-
body, the slides were washed with PBS, and incubated with Nov-
olink polymer (code 7161, Novocastra Laboratories, Newcastle 
upon Tyne, United Kingdom) for 30 minutes. Diaminobenzidine 
was used as the chromogen, and the sections were then counter-
stained with hematoxylin and coverslipped. The same antibodies 
(SP1 for ER and PgR 636 for PgR) were also used at PhenoPath 
Laboratories, using fully validated technical procedures.
The results from the ER and PgR assays were compared 
between PhenoPath Laboratories and Pathology Consultancy, 
in line with the most recent consensus of ASCO and CAP: the 
ER and PgR tests were considered positive if at least 1% of the 
tumor nuclei in the samples tested were positive, irrespective of 
the intensity of staining.6,7,30
Case selection for comparison between reference and local 
laboratories
The study group included 500 consecutive cases of invasive breast 
carcinoma received in 2008 and 2009 for ER and PgR testing by 
Pathology Consultancy that had previously been tested in 146 
different local laboratories in all geographic regions of Brazil. 
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Histological type No. cases %
Ductal carcinoma, NOS 469 93.8
Lobular carcinoma 13 2.6
Micropapillary carcinoma 5 1.0
Apocrine carcinoma 4 0.8
Tubular carcinoma 4 0.8
Papillary carcinoma 3 0.6
Metaplastic carcinoma 1 0.2
Mucinous carcinoma 1 0.2
Total 500 100.0
Table 1. Histological classification of invasive breast carcinomas 
according to World Health Organization (WHO), 2003
NOS = not otherwise specified.
These local laboratories consisted of community-based laborato-
ries with low volumes of ER and PgR testing. The cases included 
in the study were sent to the reference laboratory by oncologists 
for confirmation of breast cancer diagnosis and for ER and PgR 
retesting.
All the cases were morphologically reviewed in the reference 
laboratory by at least two different pathologists in order to con-
firm the diagnosis of invasive breast carcinoma and to classify 
the tumors in accordance with the World Health Organization 
(WHO) classification.1
Information regarding the ER and PgR testing performed by 
the local laboratories was retrieved from the immunohistochem-
ical reports, including the geographic location of the laboratory, 
details about fixation of the specimen (fixative used and fixa-
tion time), type of breast carcinoma tested (in situ or invasive 
carcinoma), use of tissue controls, IHC methodology (antibod-
ies, antigen retrieval technique and detection system specifica-
tions), ER and PgR results and interpretation criteria for report-
ing the results. Paraffin-embedded breast carcinoma tissue from 
all cases was used for ER and PgR testing in the reference labo-
ratory. The same paraffin blocks from the local laboratories were 
used. IHC was used to determine ER and PgR status, as previ-
ously described. In accordance with the most recent consensus 
of ASCO and CAP,6,7 the ER and PgR results were considered 
positive if at least 1% of the tumor nuclei in the samples tested 
were positive, irrespective of the intensity of staining. The ER 
and PgR results were interpreted blindly by experienced patholo-
gists, without knowledge of the previous results defined by local 
laboratories.
Statistical analysis
The reference and local laboratories results for ER and PgR were 
compared using Pearson’s chi-square (χ2) test. Kappa statistics 
were used as a concordance measurement. Sensitivity, speci-
ficity, false negative rate, false positive rate, positive predic-
tive value, negative predictive value, overall accuracy and the 
Youden index were calculated. The significance level used in all 
tests was 5%.31-34 
RESULTS
Validation by the reference laboratory 
As previously presented, 255 invasive breast carcinomas sam-
ples were tested for ER and PgR for validation purposes. In the 
CAP-accredited laboratory (PhenoPath Laboratories), 172 sam-
ples were considered positive and 83 were negative for ER; 164 
samples were considered positive and 91 were negative for PgR. 
The overall concordance between PhenoPath Laboratories and 
Pathology Consultancy was 98.8% (252/255 samples) and 98.4% 
(251/255 samples) for ER and PgR, respectively. For positive 
results, the concordance was 100.0% for both ER and PgR. For 
negative results, the concordance was 96.4% for ER and 95.6% 
for PgR. These results fully validate the ER and PgR testing per-
formed at Pathology Consultancy, according to recent recom-
mendations for validating ER and PgR IHC assays.6,7,30
Comparison of results between reference and local 
laboratories
The 500 cases of invasive breast carcinoma included in the study 
were classified as invasive ductal carcinoma that was not other-
wise specified (93.8%) and invasive lobular carcinoma (2.6%). 
Micropapillary, apocrine, tubular, papillary, metaplastic and 
mucinous carcinomas were rarely found (3.6%), as shown in 
Table 1. Cases from all geographic regions of Brazil were rep-
resented. Most of the cases were from the southeastern region 
(70.0%), followed by the southern (12.8%), northeastern (8.0%), 
central-western (6.6%) and northern (2.6%) regions. The total 
number of cases from each local laboratory ranged from 1 to 41 
cases.
Information about specimen fixation (including the fixative 
used and fixation time) was found in only 32 reports (6.4%) from 
local laboratories, and all of them reported that formalin was 
the fixative. Fixation time was not found in any of the reports. 
Most reports (67.6%) did not provide any information about the 
type of breast carcinoma (in situ or invasive carcinoma) that was 
tested in IHC assays. Only 209 reports (41.8%) provided infor-
mation on the use of tissue controls for IHC assays. 
The antibody used for ER testing by the local laboratories was 
not specified in 169 cases (33.8%). When the information regard-
ing ER antibody specification was available, 1D5 (53.8%), 6F11 
(24.2%) and SP1 (13.3%) antibodies were used most frequently; 
CC4-5 was employed in 16 (4.8%) cases, followed by SP4 (2.1%), 
RBT11 (1.2%) and LH2 (0.6%). The antibody used for PgR testing 
by the local laboratories was not specified in 194 cases (38.8%). 
When the information regarding PgR antibody specification was 
available, PgR 636 (36.3%), 1A6 (29.1%), 16 (13.7%) and 312 
(10.4%) antibodies were used most frequently; NCL was used 
in 7 cases (2.3%), followed by PR-2C5 (1.6%), SP2 (1.6%), 1A7 
(1.0%), RBT22 (1.0%), sp21 (1.0%), Y85 (1.0%), M3569 (0.7%) 
and PGR-NCL (0.3%). 
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Reference laboratory ER result
Negative Positive Total
Local laboratory  
ER result
Negative
n 120 31 151
% 84.5 8.7 30.2
Positive
n 22 327 349
% 15.5 91.3 69.8
Total
n 142 358 500
% 28.4 71.6 100.0
Table 2. Distribution of estrogen receptor (ER) results between reference and local laboratories (kappa statistic k = 0.744, P < 0.001; 
Pearson’s chi-square association test χ2 = 273.889, P < 0.0001)
Table 3. Distribution of progesterone receptor (PgR) results between reference and local laboratories (kappa statistic k = 0.688, P < 0.001; 
Pearson’s chi-square association test χ2 = 234.490, P < 0.0001)
Reference laboratory PgR result
Negative Positive Total
Local laboratory  
PgR result
Negative
n 163 44 207
% 84.0 14.4 41.4
Positive
n 31 262 293
% 16.0 85.6 58.6
Total
n 194 306 500
% 38.8 61.2 100.0
Authors, country and year of publication ER concordance PgR concordance
Viale et al.,22 25 countries, 2007 6058/6205 (97.6%) 4202/5237 (80.2%)
Badve et al.,23 USA, 2008 694/769 (90.2%) 649/769 (84.4%)
Gelber et al.,27 several countries, 2009 4323/4931 (87.6%) -
Wludarski et al., Brazil, 2011 (present study) 447/500 (89.4%) 425/500 (85.0%)
Table 4. Comparison of the concordance results for estrogen (ER) and progesterone (PgR) receptors between reference/central and local 
laboratories reported in the literature and by the present study
The antigen retrieval method was not specified in 198 
reports (39.6%). When available, heat-induced antigen retrieval 
was used. The detection system was not specified in 128 reports 
(25.6%). When available, LSAB (labeled streptavidin biotin) was 
used most frequently (60.5%), followed by ABC (avidin bio-
tin complex) (15.3%), “polymer” (15.3%), EnVision™ (5.9%), 
ADVANCE™ HRP (2.4%) and PAP (peroxidase anti-peroxidase) 
(0.6%).The comparison of ER and PgR results between the refer-
ence and local laboratories is shown in Tables 2 and 3. 
Using kappa statistics as a concordance measurement (κ = 
0.744; P < 0.001; 95% confidence interval 0.679-0.809), the over-
all accuracy of ER testing in local laboratories was 89.4% (447/500 
cases). ER-positive and negative results were concordant between 
the reference and local laboratories in 91.3% (327/358) and 
84.5% of the cases (120/142), respectively. Pearson’s chi-square 
(χ2) association test for ER results between the reference and 
local laboratories revealed χ2 = 273.889 (P < 0.0001), which indi-
cates a significant association in the results. The sensitivity, spec-
ificity, false negative rate, false positive rate, positive predictive 
value, negative predictive value and Youden index of ER test-
ing in local laboratories were 91.3%, 84.5%, 8.7%, 15.5%, 93.7%, 
79.5% and 75.8%, respectively. Using kappa statistics as a con-
cordance measurement (κ = 0.688; P < 0.001; 95% confidence 
interval 0.623-0.753), the overall accuracy of PgR testing in local 
laboratories was 85.0% (425/500 cases). PgR-positive and nega-
tive results were concordant between the reference and local lab-
oratories in 85.6% (262/306) and 84.0% of the cases (163/194), 
respectively. Pearson’s chi-square (χ2) association test for PgR 
results between the reference and local laboratories revealed χ2 
= 234.490 (P < 0.0001), which indicates a significant association 
in the results. The sensitivity, specificity, false negative rate, false 
positive rate, positive predictive value, negative predictive value 
and Youden index of PgR testing in local laboratories were 85.6%, 
84.0%, 14.4%, 16.0%, 89.4%, 78.7% and 69.6%, respectively.
Unfortunately, there was no comment concerning the criteria 
used for interpretation of the ER and PgR results in 155 reports 
(31.0%) and 162 reports (32.4%) from the local laboratories, 
respectively. When such information was available, the reports 
from local laboratories stated that the interpretation of the ER 
results was based on quantification of cells only (59.7%), both 
quantification of cells and intensity of immunostaining (39.7%), 
or intensity of immunostaining only (0.6%). The interpretation 
of PgR results was based on cell quantification only (60.0%), both 
cell quantification and the intensity of immunostaining (39.7%), 
or the intensity of immunostaining only (0.3%). No specification 
regarding the minimal percentage of cells necessary for the test 
to be considered positive was found in any report from the local 
laboratories.
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DISCUSSION
Brazil has a population of approximately 190 million people.35 
The incidence of breast cancer in Brazil is about 50,000 new cases 
per year,36 and it is considered to be an important public health 
problem.
Hormone receptor status should be defined in all newly diag-
nosed, invasive breast carcinomas as well as in recurrences, in 
order to determine patient eligibility for hormone therapy, which 
provides substantial survival benefit for patients with hormone-
positive tumors. Accurate determination of ER and PgR status 
is, therefore, critical for ensuring that patients receive appropri-
ate therapy.2-8,30 However, discordances in hormone receptor test-
ing using IHC have been reported in different laboratories from 
several countries, and these probably relate to technical issues, 
including delayed or inadequate fixation, non-optimized anti-
gen retrieval and diversity of interpretation and reporting of 
results.9-29 
In 2000, Rhodes et al.10 demonstrated that there was consid-
erable variability between laboratories (200 laboratories in 26 
countries) regarding ER results, especially in relation to detec-
tion of breast cancers with low ER positivity, with a false-negative 
rate ranging from 30% to 60%. This variability between laborato-
ries probably related to differences in IHC methodology, accord-
ing to these authors. 
In 2001, in a study that involved 105 laboratories, the same 
authors showed that the efficiency of the antigen retrieval step 
was the single most important contributory factor influencing 
the overall reproducibility of the hormone assays. Reliable assays 
were found in the majority of centers known to have clinically 
validated results. Inadequate assay sensitivity, with subsequent 
weak staining, was the main cause of poor and variable results 
at laboratories that used microwave antigen retrieval; heating 
times that were too short were identified as the principal contrib-
utory factor. Extension of the heating time resulted in significant 
improvement regardless of all other variables in the immunohis-
tochemical protocol. They also stated that continual participation 
in external quality assessment programs was an effective way to 
identify and improve variables that influence the reliability of 
immunohistochemical assays for ER and PgR determination, 
thereby assisting in technical validation and standardization.14 
Regitnig et al.15 investigated the variability in the results from 
ER and PgR testing performed by different laboratories in Aus-
tria. They found that the variability in the results was greater 
when participants used their own IHC staining method. In 2007, 
Viale et al.22 evaluated locally versus centrally assessed ER and 
PgR status among a significant number of breast cancer patients. 
Out of 105 tumors that were considered to be ER-negative in 
local laboratories, 81 were found to have positive cell rates of 
at least 1% at the central laboratories. Out of 6,100 tumors that 
were found locally to be ER-positive, 66 were found to have no 
staining centrally. The discordance was more marked for PgR 
than for ER. Because of these results, Regitnig et al.15 recom-
mended that the ER and PgR status should be reviewed in central 
laboratories whenever possible. Badve et al.23 showed a concor-
dance rate of 90% in ER testing between local and central labora-
tories. For PgR, the concordance between local and central lab-
oratories was 84%. A recent inquiry into ER testing practices in 
Canada revealed that approximately one third of 1,023 ER assays 
were scored falsely negative when retested in a central laboratory. 
The possible causes of such discrepancies related to turnover and 
lack of relevant training of pathologists and technologists, lack of 
appropriate quality assurance methods, and inadequate quality 
control policies and practices. The false negative ER assays were 
found to have poor fixation, negative internal controls, and/or 
absent internal controls.26 In 2009, Gelber et al.27 reported that 
4.3% of the tumors that tested ER-positive in local laboratories 
were found to be negative (false positive) on central review. More 
than 20% of the tumors that tested locally as ER-negative were 
shown to exhibit at least some expression of ER (false negative) 
on central reference laboratory review. Table 4 presents a com-
parison of the concordance results for ER and PgR between labo-
ratories reported in the literature and by the present study.
Pathology Consultancy is considered to be a reference labo-
ratory in Brazil because of its high volume of ER and PgR test-
ing (approximately 7,000 assays every year). In the present study, 
we compared the results from ER and PgR testing on 500 invasive 
breast carcinomas between a reference laboratory and 146 different 
local laboratories in Brazil. Local, low-volume laboratories from 
all geographic regions of Brazil were represented. Even though the 
overall concordance of the results from ER and PgR assays between 
the reference and local laboratories was high (89.4% for ER and 
85.0% for PgR) and the ER-positive assays were concordant in 
91.3% of the cases, the ER-negative assays were concordant in only 
84.5%, a result that is lower than the minimum recommended. The 
same was true for the PgR-positive and negative results. They were 
concordant in 85.6% and 84.0% of the cases, respectively. As pre-
viously stated, at least 90% and 95% agreement for positive and 
negative results is recommended.6,7,30 The false negative rates for 
ER and PgR testing in the local laboratories were 8.7% and 14.4%, 
respectively. This means that patients who are misclassified as hav-
ing ER-negative tumors are denied the potential benefit of hor-
mone treatment. The false positive rates for ER and PgR testing 
in the local laboratories were 15.5% and 16.0%, respectively. This 
means that patients who were misclassified as having ER-positive 
tumors will be exposed unnecessarily to the risks and costs of inef-
fectual treatment. The risks include a decrease in bone density 
with an increased fracture risk, an increased risk of thromboem-
bolic events and an increased risk of endometrial cancer.37 Fixation 
issues, lack of use of tissue controls, diverse immunohistochemical 
protocols (i.e. different antibodies and antigen retrieval methods) 
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that were probably not validated as recommended by ASCO and 
CAP, and heterogeneity in interpretation criteria for reporting the 
results could explain most of the ER and PgR testing discordances 
between the local and reference laboratories in Brazil.
CONCLUSION
This study presents relatively high concordance of the results 
from ER and PgR testing between local laboratories and a ref-
erence laboratory in Brazil, similar to findings from other coun-
tries. However, false-negative and false-positive results occur, 
which may relate to technical and interpretation issues. These 
results may be associated with erroneous treatment of breast can-
cer patients. We believe that validation of ER and PgR testing and 
standardization of the interpretation of the results, with rigorous 
quality control measures at local laboratories, are crucial. More-
over, reference laboratories could assist in validating local labo-
ratories’ ER and PgR assays. 
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